Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice
Fabrizio Cantini(Ospedale di Prato Santo Stefano), Delia Goletti(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani), Florenzo Iannone(University of Bari Aldo Moro), Giovanni Delogu(Università Cattolica del Sacro Cuore), Michele Conversano, Francesca Prignano(University of Florence), Laura Niccoli(Hospital of Prato), Alessandro Sanduzzi(Federico II University Hospital), Giacomo Garlaschi(Ospedale Policlinico San Martino), Carlotta Nannini(Hospital of Prato), Andrea Matucci(Ospedale Sacro Cuore Don Calabria)
Cited by 198
Related Papers
Mapping and predicting mortality from systemic sclerosis
|Annals of the Rheumatic Diseases|2017|699
The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination
|Nature|2001|464
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
|Journal of Infection|2020|445
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432
Grain yield, nitrogen-use efficiency and baking quality of old and modern Italian bread-wheat cultivars grown at different nitrogen levels
|European Journal of Agronomy|2003|360